DEC 15, 2020 7:05 AM PST

New combination therapy may help patients with treatment resistance

New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that could help cancer patients who have developed resistance to certain treatments. The combination therapy, which is described in the journal Cancer Discovery, holds potential for treating BRAF mutated melanoma as well as subtypes of melanoma, lung, pancreatic and colon cancers with RAS or NF1 mutations.

Conventional therapies that target the MAPK cancer pathway are limited in that they only work on cancers that have certain mutations in the BRAF cancer gene. Even in these cases, patients often experience treatment resistance and tumor recurrence is a concern for many patients. This research aimed to suppress the MAPK pathway in a unique way.

"The idea behind this study was to develop a combination treatment that helps people with common lethal cancers by eliciting durable anti-tumor responses," said senior author Roger Lo, MD, PhD, who is a professor of medicine at the David Geffen School of Medicine at UCLA. "Right now, MEK inhibitors by themselves provide limited clinical benefits, and the current MAPK pathway-targeted, combination therapy can help only certain patients with cancers harboring specific BRAF mutations."

To address this, the research team considered how a combination therapy of a MEK inhibitor and a second-generation RAF inhibitor (known as MEKi and type II RAFi) could treat cancer more effectively and deter resistance. They tested this combination on models of melanoma, non-small cell lung cancer, pancreatic cancer and colon cancer.

Photo: Pixabay

"It is quite remarkable that two drugs were able to bind to each of two proteins and sequester them from further propagating signals inside the cancer cells," said co-senior author Gatien Moriceau, PhD, who is an assistant adjunct professor at the David Geffen School of Medicine at UCLA. "The combination unexpectedly preserves killer T-cells inside the tumors, which allows them to hunt down drug-resistant tumor clones. This favorable impact on T-cells paves the way to combine MAPK-targeted therapies with anti-PD-1/L1 immune checkpoint therapy."

The combination therapy is now being tested in clinical trials for melanoma and non-small cell lung cancer.

Sources: Cancer Discovery, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
OCT 28, 2020
Cancer
Race disparities still exist among patients with lung cancer
OCT 28, 2020
Race disparities still exist among patients with lung cancer
Research published recently in the Journal of Surgical Oncology looks at the disparities in lung cancer treatment a ...
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
NOV 16, 2020
Cancer
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
NOV 16, 2020
Fingerprinting Ginger Extracts and Testing Their Anti-Cancer Abilities
Modern medicine relies on careful study and isolation of compounds or proteins, but many studies point to natural herbal ...
NOV 24, 2020
Cancer
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
NOV 24, 2020
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
Did you know sleeping is great? Apparently, getting a full eight hours every night can make you look fabulous and solve ...
DEC 03, 2020
Cancer
Lung cancers in Latin Americans with Native American ancestry
DEC 03, 2020
Lung cancers in Latin Americans with Native American ancestry
New research published in Cancer Discovery highlights the increased presence of genetic mutations in Latin American lung ...
Loading Comments...